<DOC>
	<DOCNO>NCT01540539</DOCNO>
	<brief_summary>The purpose study study safety tolerability intravenous ( IV ) subcutaneous ( SC ) administration REGN1154 normal healthy subject .</brief_summary>
	<brief_title>Intravenous/Subcutaneous FIH Study REGN1154 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>1 . Healthy men woman age 18 65 ; woman must postmenopausal surgically sterile 2 . Body mass index ( BMI ) 18.0 30.0 kg/m2 , inclusive 3 . Willing , commit , able return ALL clinic visit complete studyrelated procedure 4 . Able read understand consent process , willing sign inform consent form ( ICF ) Exclusion criterion include , limited following : 1 . Any illness condition would adversely affect subject 's participation study 2 . Any clinically significant abnormality observe screen visit 3 . Use certain medication take screen visit 4 . Onset new exercise routine major change previous exercise routine within 4 week prior screen visit 5 . Hospitalization within 60 day screen visit 6 . Any condition would place subject risk , interfere participation study 7 . History positive human immunodeficiency virus ( HIV ) screen result screen visit 8 . History certain condition 9 . Positive urine , drug alcohol screen result screen 10 . Known sensitivity component investigational product formulation 11 . Participation clinical research study evaluate another investigational drug therapy within 30 day least 5 halflives ( whichever longer ) , investigational drug prior screen visit 12 . Live/attenuated vaccination within 12 week screen study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>